À LA UNE de l'actualité médicale
BPH: benign prostatic hyperplasia
ED: emergency department
...
Patel, Parth M. et al.
The Journal of urology 2020; 204(2): 332-6
Lire la suite
Patel, Parth M. et al.
The Journal of urology 2020; 204(2): 332-6
Lire la suite
Prostate cancer is the most common solid neoplasm and the second leading cause of cancer death in men in the US [1]. Both incidence and mortality are increasing, with an estimated 60,300 new cases diagnosed and 26,600 prostate cancer-related deaths in China in 2015 [2]. Approximately one million prostate biopsies are conducted per year in the US. However, prostate-specific antigen (PSA) testing, the...
Zhao Hong-wei et al.
BMC Urology 2020; 20(1): 97
Lire la suite
Zhao Hong-wei et al.
BMC Urology 2020; 20(1): 97
Lire la suite
Approximately 52% of men over 40 years old experience erectile dysfunction (ED) and the prevalence of ED increases with age [1]. Several treatments are available, including oral phosphodiesterase type 5 inhibitors (PDE5I), vacuum devices, intraurethral and topical alprostadil, intra-cavernous injection therapy and penile implants [2].
There is a large number of disorders known to contribute to...
Jose Vinay et al.
World Journal of Urology 2020; aop: 10.1007/s00345-020-03373-y
Lire la suite
Jose Vinay et al.
World Journal of Urology 2020; aop: 10.1007/s00345-020-03373-y
Lire la suite
PCa represents the most frequent form of solid tumor and the second most common cause of cancer‐related death in the male population. A key challenge for PCa management is to provide precise information on the tumor site, grade and stage. The standard for the diagnosis of PCa has been represented by systematic TRUS‐guided biopsies in men with increased PSA or abnormal digital rectal examination...
Davide Ippolito et al.
International Journal of Urology 2020; AOP: 10.1111/iju.14316
Lire la suite
Davide Ippolito et al.
International Journal of Urology 2020; AOP: 10.1111/iju.14316
Lire la suite
In the United States, prostate cancer is the leading newly diagnosed cancer in men and is the second leading cause of cancer‐related death among men. The mainstay clinical intervention for advanced prostate cancer is androgen deprivation therapy which involves surgical and/or chemical castration to eliminate androgens in circulation. Although initially effective, many men will develop a more...
Jennifer R. Hertzog MS et al.
The Prostate 2020; AOP: 10.1002/pros.24049
Lire la suite
Jennifer R. Hertzog MS et al.
The Prostate 2020; AOP: 10.1002/pros.24049
Lire la suite
